New immunosuppressive drugs in organ transplantation

Journal of Clinical Pharmacology

Volumn 36, Issue 12, 1996, Pages 1081-1092

  Hughes, Stephen E ^a,b   Gruber, Scott A ^a,c,d  

^a ALBANY MEDICAL COLLEGE   (United States)

^b Department of Emergency Medicine ^*

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; IMMUNOSUPPRESSIVE AGENT; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEW DRUG; RAPAMYCIN;

CLINICAL TRIAL; DRUG INDUCED DISEASE; DRUG RESEARCH; DRUG SCREENING; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATION; REVIEW;

EID: 0030468653     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04160.x     Document Type: Review

References (140)

1. Halloran PF: Aspects of allograft rejection. IV. Evaluation of new pharmacologic agents for prevention of allograft rejection. Transplant Rev 1995; 9:138-146.
2. Stock PG, Lantz M, Light S, Vincenti F: In vivo (Phase I) trial and in vitro efficacy of humanized anti-Tac for the prevention of rejection in renal transplant recipients. Transplant Proc 1996; 28:915-916.
3. Kovarik JM, Rawlings E, Sweny P, Fernando O, Moore R, Griffin PJ, et al: Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD25) monoclonal antibody SDZ CHI 621 in renal transplantation. Transplant Proc 1996; 28:913-914.
4. Halloran PF, Batiuk TD, Goes NB, Campbell P: Strategies to improve the immunologic management of organ transplants. Clin Transplant 1995; 9:227-236.
5. Sehgal SN, Baker H, Vezina C: Rapamycin (AY-22,989), a new antifungal antibiotic: fermentation, isolation and characterization. J Antibiot (Tokyo) 1975; 28:727-732.
6. Vezina C, Kudelski A, Sehgal SN: Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975; 28:712-726.
7. Morris RE: Rapamycins: antifungal, antitumor, antiproliferative, and immunosuppressive macrolides. Transplant Rev 1992; 6:39-87.
8. Martel RR, Klicius J, Galet S: Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol 1977;55:48-51.
9. Morris RE: New small molecule immunosuppressants for transplantation: review of essential concepts. J Heart Lung Transplant 1993; 12(suppl):S275-S286.
10. Morris R: Modes of action of FK506, cyclosporin A, and rapamycin. Transplant Proc 1994; 26:3272-3275.
11. Morris RE: Rapamycin for transplantation. In, Kupiec-Weglinski JW (ed.): New Immunosuppressive Modalities in Organ Transplantation. Austin: R.G. Landes, 1994; 43-63.
12. Liu J, Farmer JD, Jr, Lane WS, Friedman J, Weissman I, Schreiber SL: Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK 506 complexes. Cell 1991; 66:807-815.
13. Dumont FJ, Staruch MJ, Koprak SL, Siekierka JJ, Lin S, Harrison R, et al: The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin. J Exp Med 1992; 176:751-760.
14. Bierer BE, Ji J, Fruman DA, Calvo V, Burakoff SJ: FK 506 and rapamycin: molecular probes of T-lymphocyte activation. Transplant Proc 1991; 23:2850-2855.
15. Schreiber SL, Liu J, Albers MW, Karmacharya R, Koh E, Martin PK, et al: Immunophilin-ligand complexes as probes of intra-cellular signaling pathways. Transplant Proc 1991; 23:2839-2844.
16. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, Schreiber SL: A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994; 369:756-758.
17. Dumont FJ, Staruch MJ, Koprak SL, Melino MR, Sigal NH: Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol 1990; 144:251-258.
18. Dumont FJ, Kastner CA: Transforming growth factor ß1 inhibits interleukin-1-induced but enhances ionomycin-induced inter-feron-y production in a T cell lymphoma: comparison with the effects of rapamycin. J Cell Physiol 1994; 160:141-153.
19. Morice WG, Wiederrecht G, Brunn GJ, Siekierka JJ, Abraham RT: Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes. J Biol Chem 1993; 268:22737-22745.
20. Chung J, Kuo CJ. Crabtree GR, Blenis J: Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinase. Cell 1992; 69:1227-12365.
21. Price DJ, Grove JR, Calvo V, Avruch J, Bierer BE: Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science 1992;257:973-977.
22. Kuo CJ, Chung J, Fiorentino DF, Flanagan WM, Blenis J, Crabtree GR: Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 1992; 358:70-73.
23. Jefferies HBJ, Reinhard C, Kozma SC, Thomas G: Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family. Proc Natl Acad Sci USA 1994;91:4441-4445.
24. Metcalfe SM, Richards FM: Cyclosporine, FK506, and rapamycin. Transplantation 1990;49:798-802.
25. Kay JE, Kromwel L, Doe SEA, Denyer M: Inhibition of T and B lymphocyte proliferation by rapamycin. Immunology 1991; 72:544-549.
26. Morice WG, Brunn GJ, Wiederrecht G, Siekierka JJ, Abraham RT: Rapamycin-induced inhibition of p34 cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes. J Biol Chem 1993;268:3734-3738.
27. Luo H, Duguid W, Chen H, Maheu M, Wu J: The effect of rapamycin on T cell development in mice. Eur J Immunol 1994;24:692-701.
28. Molnar-Kimber KL: Mechanism of action of rapamycin (Sirolimus, Rapamune). Transplant Proc 1996;28:964-969.
29. Yatscoff RW: Pharmacokinetics of rapamycin. Transplant Proc 1996; 28:970-973.
30. Kay JE, Sampare-Kwateng E, Geraghty F, Morgan GY: Uptake of FK 506 by lymphocytes and erythrocytes. Transplant Proc 1991;23:2760-2762.
31. Napoli KL, Wang ME, Stepkowski SM, Kahan BD: Distribution of sirolimus in rat tissue, Clin Biochem, in press.
32. Kahan BD, Murgia MG, Slaton J, Napoli K: Potential applications of therapeutic drug monitoring of sirolimus immunosuppression in clinical renal transplantation. Ther Drug Monit 1995; 17:672-675.
33. Calne RY, Collier DS, Lim S, Pollard SG, Samaan A, White DJ, Thiru S: Rapamycin for immunosuppression in organ allografting. Lancet 1989;2:227.
34. Collier DS, Calne R, Thiru S, Lim S, Pollard SG, Barron P, et al: Rapamycin in experimental renal allografts in dogs and pigs. Transplant Proc 1990;22:1674-1675.
35. Ochiai T, Gunji Y, Nagata M, Komori A, Asano T, Isono K: Effects of rapamycin in experimental organ allografting. Transplantation 1993; 56:15-19.
36. Collier DS, Calne RY, Pollard SG, Friend PJ, Thiru S: Rapamycin in experimental renal allografts in primates. Transplant Proc 1991;23:2246-2247.
37. Kaufman DB, Jones J, Matas AJ: New immunosuppressive agents: FK506, rapamycin, RS-61443, 15-deoxyspergualin. J Transplant Coordination 1992;2:20-27.
38. Murgia MG, Jordan S, Kahan BD: The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisonetreated renal transplant patients. Kidney Int 1996;49:209-216.
39. Kahan BD: Sirolimus: a new agent for clinical renal transplantation. Transplant Proc, in press.
40. Kahan BD, Gibbons S, Tejpal N, Stepkowski SM, Chou T-C: Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation 1991; 51:232-239.
41. Kahan BD: Synergism: how assessed and how achieved. Clin Transplantation 1991; 5:534-539.
42. Knight R, Ferraresso M, Serino F, Katz S, Lewis R, Kahan BD: Low-dose rapamycin potentiates the effects of subtherapeutic doses of cyclosporine to prolong renal allograft survival in the mongrel canine model. Transplantation 1993; 55:947-949.
43. MizunoK, TsujinoM, Takada M, Hayashi M, Atsumi K, Asano K, Matsuda T: Studies on bredinin. I. Isolation, characterization and biological properties. J Antibiot (Tokyo) 1974;27:775-782.
44. Sakaguchi K, Tsujino M, Mizuno K, Hayano K, Ishida N: Effect of bredinin and its aglycone on L5178Y cells. J Antibiot (Tokyo) 1975; 28:798-803.
45. Sakaguchi K, Tsujino M, Yoshizawa M, Mizuno K, Hayano K: Action of bredinin on mammalian cells. Cancer Res 1975; 35:1643-1648.
46. Sakaguchi K, Tsujino M, Hayashi M, Kawai K, Mizuno K, Hayano K: Mode of action of bredinin with guanylic acid on L5178Y mouse leukemia cells. J Antibiot (Tokyo) 1976;29:1320-1327.
47. Koyama H, Tsuji M: Genetic and biochemical studies on the activation and cytotoxic mechanism of bredinin, a potent inhibitor of purine. Biochem Pharmacol 1983; 32:3547-3553.
48. Robins RK, Revankar GR, McKernan PA, Murray BK, Kirsi JJ, North JA: The importance of IMP dehydrogenase inhibition in the broad spectrum antiviral activity of ribavirin and selenazofurin. Adv Enzyme Regul 1985;24:29-43.
49. Kusumi T, Tsuda M, Katsunuma T, Yamamura M: Dual inhibitory effect of bredinin. Cell Biochem Funct 1988; 7:201-204.
50. Yamada Y, Natsumeda Y, Yamaji Y, Weber G: Two distinct target sites on IMP dehydrogenase in chemotherapy. Adv Exp Med Biol 1989;253B:57-63.
51. Ichikawa Y, Ihara H, Takahara S, Takada K, Shrestha GR, Ishibashi M, et al: The immunosuppressive mode of action of mizoribine. Transplantation 1984; 38:262-267.
52. Hasunuma T, Yamanaka H, Terai C, Miyasaka N, Kamatani N, Nishioka K, Mikanagi K: Selective inhibition of cytotoxic T lymphocyte proliferation by mizoribine (bredinin), an adenosine analog. Adv Exp Med Biol 1989; 253A:455-460.
53. Ishibashi M, Jiang S, Kokado Y, Takahara S, Sonoda T: Immunopharmacologic effects of immunosuppressive agents explored by a new effector monocyte generation assay. Transplant Proc 1989;21:1854-1858.
54. Ichikawa Y, Ihara H, Takada K, Ishibashi M, Sagawa S: Effect of mizoribine on interleukin 2 synthesis. Transplant Proc 1984; 16:322-324.
55. Morris RE: Immunopharmacology of new xenobiotic immunosuppressive molecules. Semin Nephrol 1992; 12:304-314.
56. Mitchell BS, Dayton JS, Turka LA, Thompson CB: IMP dehydrogenase inhibitors as immunomodulators. Ann N Y Acad Sci 1993;685:217-224.
57. Turka LA, Dayton J, Sinclair G, Thompson CB, Mitchell BS: Guanine ribonucleotide depletion inhibits T cell activation: mechanism of action of the immunosuppressive drug. J Clin Invest 1991; 87:940-948.
58. Dayton JS, Turka LA, Thompson CB, Mitchell BS: Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotide metabolism. Mol Pharmacol 1992;41:671-676.
59. Lemster B, Woo J, Strednak J, Wang SC, Todo S, Starzl TE, Thomson AW: Cytokine gene expression in murine lymphocytes activated in the presence of FK 506, bredinin, mycophenolic acid, or brequinar sodium. Transplant Proc 1992; 24:2845-2846.
60. Thomson AW, Woo J, Yao GZ, Todo S, Starzl TE, Zeevi A: Effects of combined administration of FK 506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures. Transpl Immunol 1993; 1:146-150.
61. Okubo M, Chen XM, Kamata K, Masaki Y, Uchiyama T: Suppressive effect of mizoribine on humoral antibody production in DBA/2 mice. Transplantation 1986;41:495-498.
62. Murase J, Mizuno K, Kawai K, Nishiumi S, Kobayashi Y, Hayashi M, et al: Absorption, distribution, metabolism and excretion of bredinin in rats. Pharmacometrics 1978; 15:829-835.
63. Inou T, Kusaba R, Takahashi I, Sugimoto H, Kuzuhara K, Yamada Y, et al: Clinical trial of bredinin in renal transplantation. Transplant Proc 1981; 13:315-318.
64. Kusaba R, Otubo O, Inou T: Studies on pharmacokinetics of bredinin. Japanese Journal of Transplantation 1982; 17:585.
65. Takada K, Asada S, Ichikawa Y, Sonoda T, Takahara S, Nagano S, Fukunishi T: Pharmacokinetics of bredinin in renal transplant patients. Eur J Clin Pharmacol 1983; 24:457-461.
66. Takada K, Yoshikawa H, Muranishi S, Takahara S, Nagano S, Fukunishi T, et al: Elimination characteristics of bredinin from patients serum in hemodialysis. Int J Clin Pharmacol Ther Toxicol 1985; 23:197-199.
67. Kokado Y, Ishibashi M, Jiang H, Takahara S, Sonoda T: A new triple-drug induction therapy with low dose cyclosporine, mizoribine and prednisolone in renal transplantation. Transplant Proc 1989;21:1575-1578.
68. Kokado Y, Ishibashi M, Jiang H, Takahara S, Sonoda T: Lowdose ciclosporin mizoribine and prednisolone in renal transplantation: a new triple-drug therapy. Clin Transplant 1990; 4:191-197.
69. Amemiya H, Itoh H: Mizoribine (BredininR): mode of action and effects on graft rejection. In, Thomson AW, Starzl TE (eds.): Immunosuppressive Drugs: Developments in Anti-Rejection Therapy. Boston: Edward Arnold, 1994;161-176.
70. Lee HA, Slapak M, Venkatraman G, Mason JC, Digard N, Wise M: Mizoribine as an alternative to azathioprine in triple therapy immunosuppressive regimens in cadaveric: renal transplantation: two successive studies. Tranplant Proc 1995; 27:1050-1051.
71. Gregory CR, Gourley IM. Cain GR, Patz JD, Imondi KA, Martin JA: Mizoribine serum levels associated with enterotoxicity in the dog. Transplantation 1991; 51:877-881.
72. Gruber SA, Erdmann GR, Burke BA, Moss A, Bowers L, Hrushesky WJM, et al: Mizoribine pharmacokinetics and pharmacodynamics in a canine renal allograft model of local immunosuppression. Transplantation 1992; 53:12-19.
73. Zaoui P, Serre-Debeauvais F, Bayle F. Bessard G, Pintar P, Deteix P, et al: Clinical use of mizoribine (bredinin) and pharmacologic monitoring assesment in renal transplantation. Transplant Proc 1995;27:1064-1065.
74. Dayton JS, Mitchell BS: Mizoribine: immunosuppressive activity and mechanism of action. In, Przepiorka D (ed.): New Immunosuppressive Drugs. Glenview, IL: Physicians & Scientists, 1994; 129-137.
75. Kusaba R, Otubo O, Sugimoto H, Takahashi I, Yamada Y, Yamauchi J, et al: Immunosuppressive effect of bredinin in the management of patients with renal transplantation. Proc Eur Dial Transplant Assoc 1981; 18:420-425.
76. Tajima A, Hata M, Ohta N, Ohtawara Y, Suzuki K, Aso Y: Bredinin treatment in clinical kidney allografting. Transplantation 1984;38:116-118.
77. Hasegawa A, Kawamura T, Ogawa O, Kato S, Honda M, Nakahara C, et al: Clinical trial of bredinin in pediatric renal transplants. Transplant Proc 1985; 17:1324-1329.
78. Sato K, Matsuzawa K, Tadokoro F, Kakita A, Okubo M, Kumano K, et al: Studies of immunosuppression with quadruple regimen treatment (cyclosporine, mizoribine, prednisolone, and antilymphocyte globulin) in cadaveric and living-related donor renal allotransplantation, Transplant Proc 1992; 24:1383-1385.
79. Uchida H, Mita K, Bekku Y, Nishimura Y, Ishida Y, Watanabe K, et al: Advantages of triple therapy with mizoribine, cyclosporine and prednisolone over other types of triple and/or double therapy including cyclosporine for renal transplantation. J Toxicol Sci 1991; 16:181-190.
80. Lee HA, Slapak M, Venkatraman G, Mason J, Digard N, Wise M: Mizoribine as an alternative to azathioprine in triple-therapy immunosuppressant regimens in cadaveric renal transplantation. Transplant Proc 1993; 25:2699-2700.
81. Franklin TJ, Cook JM: The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 1969; 113:515-524.
82. Mitsui A, Suzuki S: Immunosuppressive effect of mycophenolic acid. J Antibiot (Tokyo) 1969; 22:358-363.
83. Ohsugi Y, Suzuki S, Takagaki Y: Antitumor and immunosuppressive effects of mycophenolic acid derivatives. Cancer Res 1976;36:2923-2927.
84. Lee WA, Gu L, Miksztal AR, Chu N, Leung K, Nelson PH: Bioavailability improvement of mycophenolic acid through amino ester derivitization. Pharmaceut Res 1990;7:161-166.
85. Allison AC, Eugui EM: Mycophenolate mofetil, a rationally designed immunosuppressive drug. Clin Transplant 1993; 7:96-112.
86. Nagai M, Natsumeda Y, Weber G: Proliferation-linked regulation of the type II IMP dehydrogenase gene in normal human lymphocytes and HL-60 leukemic cells. Cancer Res 1992; 52:258-261.
87. Allison AC, Hovi T, Watts RWE, Webster ADB: The role of de novo purine synthesis in lymphocyte transformation. Ciba Found Symp 1977; 48:207-223.
88. Zeevi A, Woan M, Yao G-Z, Venkataramanan R, Todo S, Starzl TE, Duquesnoy RJ: Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK 506, cyclosporine, and rapamycin, Transplant Proc 1991; 23:2928-2930.
89. Zeevi A, Yao GZ, Venkataramanan R, Duquesnoy RJ, Todo S, Fung JJ, Starzl TE: Comparative in vitro studies on the immunosuppressive effects of purine and pyrimidine synthesis inhibitors. Transplant Proc 1993;25:781-783.
90. Eugui EM, Almquist S, Muller CD, Allison AC: Lymphocyte-selectiva cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991; 33:161-173.
91. Allison AC: Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation. Transplant Proc 1994; 26:3205-3210.
92. Li S, Yatscoff RW: Improved high-performance liquid chromatographic assay for the measurement of mycophenolic acid in human plasma. Transplant Proc 1996;28:938-940.
93. Bullingham RES, Nicholls A, Hale M: Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc 1996;28:925-929.
94. Bullingham R, Monroe S, Nicholls A, Hale M: Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 1996; 36:315-324.
95. Platz KP, Sollinger HW, Hullett DA, Eckhoff DE, Eugui EM, Allison AC: RS-61443 - a new, potent immunosuppressive agent. Transplantation 1991; 51:27-31.
96. Goldblum R: Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol 1993; 11(suppl 8):S117-S119.
97. Sollinger HW, Deierhoi MH, Belzer FO, Diethelm AG, Belzer FO, Kauffman RS: RS-61443: a phase I clinical trial and pilot rescue study. Transplantation 1992; 53:428-432.
98. Sollinger HW, Belzer FO, Deierhoi MH, Diethelm AG, Gonwa TA, Kauffman RS, et al: RS-61443 (mycophenolate mofetil): a multicenter study for refractory kidney transplant rejection. Ann Surg 1992;216:513-519.
99. Sollinger HW: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60:225-232.
100. Takeuchi T, Iinuma H, Kunimoto S, Masuda T, Ishizuka M, Takeuchi M, et al: A new antitumor antibiotic, spergualin: isolation and antitumor activity. J Antibiot (Tokyo) 1981;34:1619-1621.
101. Iwasawa H, Kondo S, Ikeda D, Takeuchi T, Umezawa H: Synthesis of (-)-15- deoxyspergualin and (-)-spergualin-15-phosphate. J Antibiot (Tokyo) 1982; 35:1665-1669.
102. Dickneite G, Walter P, Schorlemmer HU: The immunosuppressive properties of 15-deoxyspergualin and its effects on experimental skin and islet cell transplantation. In, Ishigami J (ed.): Recent Advances in Chemotherapy. Tokyo: University of Tokyo Press, 1985;949-950.
103. Suzuki S, Kanashiro M, Amemiya H: Effect of a new immunosuppressant, 15-deoxyspergualin, on heterotopic rat heart transplantation, in comparison with cyclosporine. Transplantation 1987;44:483-487.
104. Dickneite G, Schorlemmer HU, Sedlacek HH: Decrease of mononuclear phagocyte cell functions and prolongation of graft survivial in experimental transplantation by (±)-15- deoxyspergualin. Int J Immunopharmacol 1987; 9:559-565.
105. Nemoto K, Hayashi M, Abe F, Takita T, Takeuchi T: Inhibition by 15-deoxyspergualin of allo-reactive cytotoxic activity in mouse graft-versus-host disease. Transplant Proc 1989; 21:3028-3030.
106. Nishimura K, Tokunaga T: Effects of 15-deoxyspergualin on the induction of cytotoxic T lymphocytes and bone marrow suppression. Transplant Proc 1989; 21:1104-1107.
107. Fujii H, Takada T, Nemoto K, Abe F, Fujii A, Takeuchi T: In vitro immunosuppressive properties of spergualins to murine T cell response. J Antibiot (Tokyo) 1989; 42:788-794.
108. Valdivia LA, Monden M, Gotoh M, Nakano Y, Tono T, Mori T: Evidence that deoxyspergualin prevents sensitization and first-set cardiac xenograft rejection in rats by suppression of antibody formation. Transplantation 1990;1990:132-136.
109. Tepper MA, Petty B, Bursuker I, Pasternak RD, Cleaveland J, Spitalny GL, Schacter B: Inhibition of antibody production by the immunosuppressive agent, 15-deoxyspergualin. Transplant Proc 1991; 23:328-331.
110. Leventhal JR, Flores HC, Gruber SA, Figueroa J, Platt JL, Manivel JC, et al: Evidence that 15-deoxyspergualin inhibits natural antibody production but fails to prevent hyperacute rejection in a discordant xenograft model. Transplantation 1992; 54:26-31.
111. Morikawa K, Oseko F, Morikawa S: The suppressive effect of deoxyspergualin on the differentiation of human B lymphocytes maturing into immunoglobulin-producing cells. Transplantation 1992; 54:526-531.
112. Zhu X, Imamura M, Tanaka J, Han CW, Hashino S, Imai K, et al: Effects of 15-deoxyspergualin in vitro and in vivo on cytokine gene expression. Transplantation 1994; 58:1104-1109.
113. Hiratsuka M, Kuramochi H, Takahashi K, Takeuchi T, Oshimura M: Cytostatic effect of deoxyspergualin on a murine leukemia cell line L1210. Jpn J Cancer Res 1991; 82:1065-1068.
114. Hibasami H, Tsukada T, Suzuki R, Takano K, Takaji S, Takeuchi T, et al: 15-Deoxyspergualin, an antiproliferative agent for human and mouse leukemia cells, shows inhibitory effects on the synthetic pathway of polyamines. Anticancer Res 1991; 11:325-330.
115. Nadler SC, Tepper MA, Schacter B, Mazzucco CE: Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp70 family of heat shock proteins. Science 1992; 258:484-486.
116. Nadeau K, Nadler SG, Saulnier M, Tepper MA, Walsh CT; Quantitation of the interaction of the immunosuppressant deoxyspergualin and analogs with Hsc70 and Hsp90. Biochemistry 1994; 33:2561-2567.
117. VanBuskirk AM, Denagel DC, Guagliardi LE, Brodsky FM, Pierce SK: Cellular and subcellular distribution of PBP72/74, a peptide binding protein that plays a role in antigen processing. J Immunol 1991;146:500-506.
118. Amemiya H: 15-Deoxyspergualin. In, Kupiec-Weglinski J (ed.): New Immunosuppressive Modalities in Organ Transplantation. Austin, TX: R.G. Landes, 1994; 75-91.
119. Hoeger PH, Tepper MA, Faith A, Higgins JA, Lamb JR, Geha RS: Immunosuppressant deoxyspergualin inhibits antigen processing in monocytes. J Immunol 1994; 153:3908-3916.
120. Sprancmanis LA, Riley CM, Stobaugh JF: Determination of the anticancer drug, 15-deoxyspergualin, in plasma ultrfiltrate by liquid chromatography and precolumn derivatization with naphthalene-2,3-dicarboxaldehyde/cyanide. J Pharm Biomed Anal 1990;8:165-175.
121. Thomas FT, Tepper MA, Thomas JM, Haisch CE: 15-Deoxyspergualin: a novel immunosuppressive drug with clinical potential. Ann N Y Acad Sci 1993;685:175-192.
122. Ramos EL, Nadler SG, Grasela DM, Kelley SL: Deoxyspergualin: mechansim of action and pharmacokinetics. Transplant Proc 1996; 28:873-875.
123. Ohlman S, Zilg H, Schindel F, Lindholm A: Pharmacokinetics of 15-deoxyspergualin studied in renal transplant patients receiving the drug during graft rejection. Transpl Int 1994; 7:5-10.
124. Muindi JF, Lee S-J, Baltzer L, Jakubowski A, Scher HI, Sprancmanis LA, et al: Clinical pharmacology of deoxyspergualin in patients with advanced cancer. Cancer Res 1991; 51:3096-3101.
125. Amemiya H, Suzuki S, Manabe H, Fukao K, Iwasaki Y, Dohi K, et al: 15-Deoxyspergualin as an immunosuppressive agent in dogs. Transplant Proc 1988; 20(suppl 1):229-232.
126. Collier DSJ, Calne R, Thiru S, Kohno H, Levickis J: 15-Deoxyspergualin in experimental dog renal allografts. Transplant Proc 1988; 20(suppl 1):240-241.
127. Todo S, Murase N, Kahn D, Pan CE, Okuda K, Cemej S, et al: Effect of 15-deoxyspergualin on experimental organ transplantation. Transplant Proc 1988; 20(suppl 1):233-236.
128. Amemiya H, Suzuki S, Niiya S, Fukao K, Yamanaka N, Ito J: A new immunosuppressive agent, 15-deoxyspergualin, in dog renal allografting. Transplant Proc 1989; 21:3468-3470.
129. Koyama I, Kadokura M, Hoshino T, Omoto R: Effective use of 15-deoxyspergualin in kidney transplantation. Transplant Proc 1989;21:1088-1089.
130. Suzuki S: FK506 and deoxyspergualin: experimental studies and clinical applications. Transpl Immunol 1994; 2:190-198.
131. Koyama I, Amemiya H, Taguchi Y, Watanabe T, Nagashima N, Suzuki S, Omoto R: Prophylactic use of deoxyspergualin in a quadruple immunosuppressive protocol in renal transplantation. Transplant Proc 1991;23:1096-1098.
132. Okazaki H, Sato T, Jimbo M, Senga S, Amada N, Oguma S: Prophylactic use of deoxyspergualin in living related renal transplantation. Transplant Proc 1991; 23:1094-1095.
133. Amemiya H, Ota K, Sonoda T, Fukao K, Taguchi Y, Isono K, et al: Pulse therapy for rejection with deoxyspergualin in renal recipients: a multicenter controlled study. Transplant Proc 1992;24:1375-1376.
134. Jiang H, Takahara S, Takano Y, Kokado Y, Kameoka H, Mou-tabarrik A, et al: Experience with administration of 15-deoxyspergualin in rejection in kidney transplant recipients. Transplant Proc 1992;24:1726-1729.
135. Amemiya H, Suzuki S, Ota K, Takahashi K, Sonoda T, Ishibashi M, et al: A novel rescue drug, 15-deoxyspergualin: first clinical trials for recurrent graft rejection in renal recipients. Transplantation 1990;49:337-343.
136. Kyo M, Ichikawa Y, Fukunishi Y, Hanafusa T, Nagano S, Takahara S, et al: Histopathological classification and clinical effects of kidney transplant rejection treated with 15-deoxyspergualin. Transplant Proc 1995; 27:1012-1013.
137. Matas AJ, Gores PF, Kelley SL, Bielefield-Skrokov M, Kinaszcuk M, Gruessner RWG, Najarian JS: Pilot evaluation of 15-deoxyspergualin for refractory acute renal transplant rejection. Clin Transplant 1994;8:116-119.
138. Groth CG, Ohlman S, Ericzon BG, Barkholt L, Reinholt FP: Deoxyspergualin for liver graft rejection (letter). Lancet 1990; 336:626.
139. Gores PF, Najarian JS, Stephanien E, Lloveras JJ, Kelley SL, Sutherland DE: Insulin independence in type I diabetes after transplantation of unpurified islets from single donor with 15-deoxyspergualin. Lancet 1993; 341:19-21.
140. Groth CG: Deoxyspergualin in allogeneic kidney and xenogeneic islet transplantation: early clinical trials. Ann N Y Acad Sci 1993; 685:193-195.